Terms: = Lung cancer AND HER1, YOR227W
120 results:
1. Design and Evaluation of a Humanized Anti-EGFR huscFv Antibody Fragment in Combination With Metformin in A549 Cells
Solis-Estrada J; Arredondo-Espinoza E; Pioquinto-Ávila E; González-Cruz AO; Zarate X; Balderas-Rentería I
Anticancer Res; 2024 May; 44(5):1955-1962. PubMed ID: 38677771
[TBL] [Abstract] [Full Text] [Related]
2. Zerumbone-incorporated liquid crystalline nanoparticles inhibit proliferation and migration of non-small-cell lung cancer in vitro.
Manandhar B; Paudel KR; Clarence DD; De Rubis G; Madheswaran T; Panneerselvam J; Zacconi FC; Williams KA; Pont LG; Warkiani ME; MacLoughlin R; Oliver BG; Gupta G; Singh SK; Chellappan DK; Hansbro PM; Dua K
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):343-356. PubMed ID: 37439806
[TBL] [Abstract] [Full Text] [Related]
3. Small Molecule EGFR Inhibitors as Anti-cancer Agents: Discovery, Mechanisms of Action, and Opportunities.
Zubair T; Bandyopadhyay D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768973
[TBL] [Abstract] [Full Text] [Related]
4. In Situ Hybridization (ISH) Combined with Immunohistochemistry (IHC) for Co-detection of EGFR RNA and Phosphorylated EGFR Protein in lung cancer Tissue.
Oliver A; Hagen J; Yang S; Kalyuzhny AE
Methods Mol Biol; 2023; 2593():221-232. PubMed ID: 36513934
[TBL] [Abstract] [Full Text] [Related]
5. Based on lapatinib innovative near-infrared fluorescent probes targeting her1/HER2 for in vivo tumors imaging.
Li C; Lin Q; Hu F; Bao R; Cai H; Gu Y
Biosens Bioelectron; 2022 Oct; 214():114503. PubMed ID: 35779413
[TBL] [Abstract] [Full Text] [Related]
6. Recent advances in the development of EGFR degraders: PROTACs and LYTACs.
Hong D; Zhou B; Zhang B; Ren H; Zhu L; Zheng G; Ge M; Ge J
Eur J Med Chem; 2022 Sep; 239():114533. PubMed ID: 35728507
[TBL] [Abstract] [Full Text] [Related]
7. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
8. Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress.
Sharma B; Singh VJ; Chawla PA
Bioorg Chem; 2021 Nov; 116():105393. PubMed ID: 34628226
[TBL] [Abstract] [Full Text] [Related]
9. Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of her1-or HER2-targeted drugs.
Okita K; Imai K; Kato K; Sugiura R; Endo Y; Masuko K; Tomioka Y; Masuko T
Biochem Biophys Res Commun; 2021 Oct; 576():59-65. PubMed ID: 34482024
[TBL] [Abstract] [Full Text] [Related]
10. Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.
Liu R; Ota K; Iwama E; Yoneshima Y; Tanaka K; Inoue H; Tagawa T; Oda Y; Mori M; Nakanishi Y; Okamoto I
Lung Cancer; 2021 Aug; 158():156-161. PubMed ID: 34059353
[TBL] [Abstract] [Full Text] [Related]
11. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
12. erbB in NSCLC as a molecular target: current evidences and future directions.
Del Re M; Cucchiara F; Petrini I; Fogli S; Passaro A; Crucitta S; Attili I; De Marinis F; Chella A; Danesi R
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32820012
[TBL] [Abstract] [Full Text] [Related]
13. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract] [Full Text] [Related]
14. Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer.
Maisel SA; Broka D; Atwell B; Bunch T; Kupp R; Singh SK; Mehta S; Schroeder J
J Transl Med; 2019 Jun; 17(1):201. PubMed ID: 31215437
[TBL] [Abstract] [Full Text] [Related]
15. Dacomitinib: First Global Approval.
Shirley M
Drugs; 2018 Dec; 78(18):1947-1953. PubMed ID: 30506139
[TBL] [Abstract] [Full Text] [Related]
16. Development of epidermal growth factor receptor targeted therapy in pancreatic cancer.
Qing L; Qing W
Minerva Chir; 2018 Oct; 73(5):488-496. PubMed ID: 29397631
[TBL] [Abstract] [Full Text] [Related]
17. Neratinib: First Global Approval.
Deeks ED
Drugs; 2017 Oct; 77(15):1695-1704. PubMed ID: 28884417
[TBL] [Abstract] [Full Text] [Related]
18. ErbB Receptors and cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract] [Full Text] [Related]
19. The prospect of patritumab for treating non-small cell lung cancer.
Horinouchi H
Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
[TBL] [Abstract] [Full Text] [Related]
20. Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule.
Dobosz M; Haupt U; Scheuer W
MAbs; 2017 Jan; 9(1):140-153. PubMed ID: 27661454
[TBL] [Abstract] [Full Text] [Related]
[Next]